|
|
Article: Beacon Equity Research Announces Investment Opinion: Advanced Viral Research Corp. Rated 'Speculative Buy,' Target $.36 by Beacon Equity Research.
- Article from:
- Business Wire
- Article date:
- May 11, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DALLAS -- Advanced Viral Research Corp. (OTCBB: ADVR) has been rated "Speculative Buy," with a price target of $.36 by Beacon Equity Research. The report is authored by Senior Research Analyst, Kris Goldcross, CFA.
The full report is available at http://www.beaconequityresearch.com
In the report, Mr. Goldcross writes, "Advanced Viral Research currently holds a diverse and sizable patent portfolio consisting of thirteen U.S. patents, two Australian patents, one Mexican patent, one Israeli patent, and two patents in China. These patents are related to the usages of AVR118, including its use in the topical treatment of skin diseases and eye afflictions. ...